Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03952065 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jan 1, 2025 to Jan 1, 2029
    • Study completion date: Jan 1, 2029 to Jan 1, 2035
    • Study description expanded, about 3 words
    v7
  2. Phase: Phase 3 to Phase 2/3v6 Show 5 more changesShow less
    • Enrollment target: 100 to 200
    • Interventions: PD1/PDL1 inhibitor (Drug) to PD1/PDL1/CTLA4 inhibitors (Drug)
    • Study description expanded, about 6 words
    • Study title revised
    • Study arms: 2 to 3
  3. Primary completion date: Jan 1, 2022 to Jan 1, 2025
    • Study completion date: Jan 1, 2022 to Jan 1, 2029
    v5
  4. Site contact updatedv4
  5. Interventions: Toripalimab (Drug) to PD1/PDL1 inhibitor (Drug)
    • Study description revised
    • Study title expanded, about 1 word
    v3
  6. Primary and study completion dates: Jan 1, 2021 to Jan 1, 2022v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial was designed to investigate the survival outcomes, response rates, and safety of patients with advanced Head/Neck Squamous cancer via intra-tumor or intra-artery versus vein infusion of PD1/PDL1/CTLA4 inhibitor or their combinations.
Trial Details
NCT Number NCT03952065
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions
(from sponsor)		 Head/Neck Neoplasm
Related terms Head and Neck Neoplasms
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov